304 related articles for article (PubMed ID: 34668836)
21. Uniform carboxymethyl chitosan-enveloped Pluronic F68/poly(lactic-co-glycolic acid) nano-vehicles for facilitated oral delivery of gefitinib, a poorly soluble antitumor compound.
Wang J; Wang F; Li X; Zhou Y; Wang H; Zhang Y
Colloids Surf B Biointerfaces; 2019 May; 177():425-432. PubMed ID: 30798063
[TBL] [Abstract][Full Text] [Related]
22. Optimized phospholipid-based nanoparticles for inner ear drug delivery and therapy.
Yang KJ; Son J; Jung SY; Yi G; Yoo J; Kim DK; Koo H
Biomaterials; 2018 Jul; 171():133-143. PubMed ID: 29689410
[TBL] [Abstract][Full Text] [Related]
23. SP-D loaded PLGA nanoparticles as drug delivery system for prevention and treatment of premature infant's lung diseases.
Attias Cohen S; Kingma PS; Whitsett JA; Goldbart R; Traitel T; Kost J
Int J Pharm; 2020 Jul; 585():119387. PubMed ID: 32473376
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal administration of dexamethasone-loaded PLGA-TPGS nanoparticles for the treatment of posterior segment diseases.
Yang C; Jiang L; Bu S; Zhang L; Xie X; Zeng Q; Zhu D; Zheng Y
J Biomed Nanotechnol; 2013 Sep; 9(9):1617-23. PubMed ID: 23980509
[TBL] [Abstract][Full Text] [Related]
25. Nanoparticle-based topical ophthalmic formulation for sustained release of stereoisomeric dipeptide prodrugs of ganciclovir.
Yang X; Shah SJ; Wang Z; Agrahari V; Pal D; Mitra AK
Drug Deliv; 2016 Sep; 23(7):2399-2409. PubMed ID: 25564964
[TBL] [Abstract][Full Text] [Related]
26. Melatonin loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles reduce inflammation, inhibit apoptosis and protect rat's liver from the hazardous effects of CCL4.
Farid A; Michael V; Safwat G
Sci Rep; 2023 Sep; 13(1):16424. PubMed ID: 37777583
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel/methotrexate co-loaded PLGA nanoparticles in glioblastoma treatment: Formulation development and in vitro antitumor activity evaluation.
Madani F; Esnaashari SS; Bergonzi MC; Webster TJ; Younes HM; Khosravani M; Adabi M
Life Sci; 2020 Sep; 256():117943. PubMed ID: 32531377
[TBL] [Abstract][Full Text] [Related]
28. Induction of antigen-specific immune tolerance using biodegradable nanoparticles containing antigen and dexamethasone.
Kim SH; Moon JH; Jeong SU; Jung HH; Park CS; Hwang BY; Lee CK
Int J Nanomedicine; 2019; 14():5229-5242. PubMed ID: 31371958
[TBL] [Abstract][Full Text] [Related]
29. Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin.
Samkange T; D'Souza S; Obikeze K; Dube A
J Pharm Pharmacol; 2019 Oct; 71(10):1497-1507. PubMed ID: 31385295
[TBL] [Abstract][Full Text] [Related]
30. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
Lee C; Choi JS; Kim I; Oh KT; Lee ES; Park ES; Lee KC; Youn YS
Int J Nanomedicine; 2013; 8():2975-83. PubMed ID: 23976850
[TBL] [Abstract][Full Text] [Related]
31. Formulation and evaluation of butenafine loaded PLGA-nanoparticulate laden chitosan nano gel.
Alshehri S; Imam SS
Drug Deliv; 2021 Dec; 28(1):2348-2360. PubMed ID: 34747275
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, physicochemical, rheological and in-vitro characterization of double-crosslinked hyaluronic acid hydrogels containing dexamethasone and PLGA/dexamethasone nanoparticles as hybrid systems for specific medical applications.
Mousavi Nejad Z; Torabinejad B; Davachi SM; Zamanian A; Saeedi Garakani S; Najafi F; Nezafati N
Int J Biol Macromol; 2019 Apr; 126():193-208. PubMed ID: 30583002
[TBL] [Abstract][Full Text] [Related]
33. Poly-(Lactic-co-Glycolic) Acid Nanoparticles for Synergistic Delivery of Epirubicin and Paclitaxel to Human Lung Cancer Cells.
Sharma N; Kumari RM; Gupta N; Syed A; Bahkali AH; Nimesh S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32947799
[TBL] [Abstract][Full Text] [Related]
34. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery.
Kim DH; Martin DC
Biomaterials; 2006 May; 27(15):3031-7. PubMed ID: 16443270
[TBL] [Abstract][Full Text] [Related]
35. Sonication tailored enhance cytotoxicity of naringenin nanoparticle in pancreatic cancer: design, optimization, and
Akhter MH; Kumar S; Nomani S
Drug Dev Ind Pharm; 2020 Apr; 46(4):659-672. PubMed ID: 32208984
[No Abstract] [Full Text] [Related]
36. Formulation and evaluation of tacrolimus-loaded galactosylated Poly(lactic-co-glycolic acid) nanoparticles for liver targeting.
Mistry NP; Desai JL; Thakkar HP
J Pharm Pharmacol; 2015 Oct; 67(10):1337-48. PubMed ID: 25944126
[TBL] [Abstract][Full Text] [Related]
37. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced.
Song X; Wang J; Xu Y; Shao H; Gu J
Colloids Surf B Biointerfaces; 2019 Aug; 180():110-117. PubMed ID: 31030022
[TBL] [Abstract][Full Text] [Related]
38. Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis.
Andreu V; Larrea A; Rodriguez-Fernandez P; Alfaro S; Gracia B; Lucía A; Usón L; Gomez AC; Mendoza G; Lacoma A; Dominguez J; Prat C; Sebastian V; Ainsa JA; Arruebo M
Nanomedicine (Lond); 2019 Mar; 14(6):707-726. PubMed ID: 30734643
[TBL] [Abstract][Full Text] [Related]
39. Long-term corticosteroid-induced chronic glaucoma model produced by intracameral injection of dexamethasone-loaded PLGA microspheres.
Rodrigo MJ; Garcia-Herranz D; Aragón-Navas A; Subias M; Martinez-Rincón T; Mendez-Martínez S; Cardiel MJ; García-Feijoo J; Ruberte J; Herrero-Vanrell R; Pablo L; Garcia-Martin E; Bravo-Osuna I
Drug Deliv; 2021 Dec; 28(1):2427-2446. PubMed ID: 34763590
[TBL] [Abstract][Full Text] [Related]
40. Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells.
Şengel-Türk CT; Hasçiçek C; Dogan AL; Esendagli G; Guc D; Gönül N
Drug Dev Ind Pharm; 2012 Sep; 38(9):1107-16. PubMed ID: 22348284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
